|
1
|
Siegel RL, Giaquinto AN and Jemal A:
Cancer statistics, 2024. CA Cancer J Clin. 74:12–49. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jassim A, Rahrmann EP, Simons BD and
Gilbertson RJ: Cancers make their own luck: Theories of cancer
origins. Nat Rev Cancer. 23:710–724. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Forbes BE, Blyth AJ and Wit JM: Disorders
of IGFs and IGF-1R signaling pathways. Mol Cell Endocrinol.
518:1110352020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Froesch ER, Buergi H, Ramseier EB, Bally P
and Labhart A: antibody-suppressible and nonsuppressible
insulin-like activities in human serum and their physiologic
significance. an insulin assay with adipose tissue of increased
precision and specificity. J Clin Invest. 42:1816–1834. 1963.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rinderknecht E and Humbel RE: The amino
acid sequence of human insulin-like growth factor I and its
structural homology with proinsulin. J Biol Chem. 253:2769–2776.
1978. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang J, Zhu Q, Cao D, Peng Q, Zhang X, Li
C, Zhang C, Zhou BO and Yue R: Bone marrow-derived IGF-1
orchestrates maintenance and regeneration of the adult skeleton.
Proc Natl Acad Sci USA. 120:e22037791202023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guan X, Yan Q, Wang D, Du G and Zhou J:
IGF-1 signaling regulates mitochondrial remodeling during myogenic
differentiation. Nutrients. 14:12492022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Matsushita M, Fujita K, Hatano K, De
Velasco MA, Uemura H and Nonomura N: Connecting the dots between
the gut-IGF-1-prostate axis: A role of IGF-1 in prostate
carcinogenesis. Front Endocrinol (Lausanne). 13:8523822022.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
LeRoith D, Holly JMP and Forbes BE:
Insulin-like growth factors: Ligands, binding proteins and
receptors. Mol Metab. 52:1012452021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dixit M, Poudel SB and Yakar S: Effects of
GH/IGF axis on bone and cartilage. Mol Cell Endocrinol.
519:1110522021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vassilakos G, Lei H, Yang Y, Puglise J,
Matheny M, Durzynska J, Ozery M, Bennett K, Spradlin R, Bonanno H,
et al: Deletion of muscle IGF-I transiently impairs growth and
progressively disrupts glucose homeostasis in male mice. FASEB J.
33:181–194. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alberini CM and Chen DY: Memory
enhancement: Consolidation, reconsolidation and insulin-like growth
factor 2. Trends Neurosci. 35:274–283. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Alfares MN, Perks CM, Hamilton-Shield JP
and Holly JMP: Insulin-like growth factor-II in adipocyte
regulation: Depot-specific actions suggest a potential role
limiting excess visceral adiposity. Am J Physiol Endocrinol Metab.
315:E1098–E1107. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ghafari F, Alizadeh AM, Agah S, Irani S
and Mokhtare M: Insulin-like growth factor 1 serum levels in
different stages of gastric cancer and their association with
Helicobacter pylori status. Peptides. 158:1708922022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kasprzak A: Autophagy and the insulin-like
growth factor (IGF) system in colonic cells: Implications for
colorectal neoplasia. Int J Mol Sci. 24:36652023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Adachi Y, Nojima M, Mori M, Himori R, Kubo
T, Akutsu N, Lin Y, Kurozawa Y, Wakai K and Tamakoshi A; Japan
Collaborative Cohort Study, : Insulin-like growth factor 2 and
incidence of liver cancer in a nested case-control study. Cancer
Epidemiol Biomarkers Prev. 30:2130–2135. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stefani C, Miricescu D, Stanescu-Spinu II,
Nica RI, Greabu M, Totan AR and Jinga M: Growth Factors,
PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer
Pathogenesis: Where Are We Now? Int J Mol Sci. 22:102602021.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feng L, Li B, Xi Y, Cai M and Tian Z:
Aerobic exercise and resistance exercise alleviate skeletal muscle
atrophy through IGF-1/IGF-1R-PI3K/Akt pathway in mice with
myocardial infarction. Am J Physiol Cell Physiol. 322:C164–C176.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fang WY, Tseng YT, Lee TY, Fu YC, Chang
WH, Lo WW, Lin CL and Lo YC: Triptolide prevents LPS-induced
skeletal muscle atrophy via inhibiting NF-κB/TNF-α and regulating
protein synthesis/degradation pathway. Br J Pharmacol.
178:2998–3016. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
de Visser KE and Joyce JA: The evolving
tumor microenvironment: From cancer initiation to metastatic
outgrowth. Cancer Cell. 41:374–403. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Paredes F, Williams HC and San Martin A:
Metabolic adaptation in hypoxia and cancer. Cancer Lett.
502:133–142. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu Y, Liu J, Tian Z, Zhang Z, Liu T, Chen
C, Tang X and Zhu J: Highly expressed IFITM10 is associated with
early diagnosis and T stage of gastric cancer. Transl Cancer Res.
10:382–392. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Seo GS, Lee JK, Yu JI, Yun KJ, Chae SC and
Choi SC: Identification of the polymorphisms in IFITM3 gene and
their association in a Korean population with ulcerative colitis.
Exp Mol Med. 42:99–104. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu L, Zhou R, Yuan L, Wang S, Li X, Ma H,
Zhou M, Pan C, Zhang J, Huang N, et al: IGF1/IGF1R/STAT3
signaling-inducible IFITM2 promotes gastric cancer growth and
metastasis. Cancer Lett. 393:76–85. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Le Coz V, Zhu C, Devocelle A, Vazquez A,
Boucheix C, Azzi S, Gallerne C, Eid P, Lecourt S and Giron-Michel
J: IGF-1 contributes to the expansion of melanoma-initiating cells
through an epithelial-mesenchymal transition process. Oncotarget.
7:82511–82527. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sarkissyan S, Sarkissyan M, Wu Y, Cardenas
J, Koeffler HP and Vadgama JV: IGF-1 regulates Cyr61 induced breast
cancer cell proliferation and invasion. PLoS One. 9:e1035342014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chiu YF, Wu CC, Kuo MH, Miao CC, Zheng MY,
Chen PY, Lin SC, Chang JL, Wang YH and Chou YT: Critical role of
SOX2-IGF2 signaling in aggressiveness of bladder cancer. Sci Rep.
10:82612020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tsai YF, Chou HC, Liou MH, Liao EC, Cheng
CT, Chang SJ and Chan HL: Role of IGFBP-2 in oral cancer
metastasis. Biochim Biophys Acta Mol Basis Dis. 1867:1661432021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Luo C, Sun F, Zhu H, Ni Y, Fang J, Liu Y,
Shao S, Shen H and Hu J: Insulin-like growth factor binding
protein-1 (IGFBP-1) upregulated by Helicobacter pylori and is
associated with gastric cancer cells migration. Pathol Res Pract.
213:1029–1036. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mo W, Deng L, Cheng Y, Ge S and Wang J:
IGFBP7 regulates cell proliferation and migration through JAK/STAT
pathway in gastric cancer and is regulated by DNA and RNA
methylation. J Cell Mol Med. 28:e700802024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu ZL, Chen HH, Zheng LL, Sun LP and Shi
L: Angiogenic signaling pathways and anti-angiogenic therapy for
cancer. Signal Transduct Target Ther. 8:1982023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ren F, Wu K, Yang Y, Yang Y, Wang Y and Li
J: Dandelion polysaccharide exerts anti-angiogenesis effect on
hepatocellular carcinoma by regulating VEGF/HIF-1α expression.
Front Pharmacol. 11:4602020. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Higashi Y, Pandey A, Goodwin B and
Delafontaine P: Insulin-like growth factor-1 regulates glutathione
peroxidase expression and activity in vascular endothelial cells:
Implications for atheroprotective actions of insulin-like growth
factor-1. Biochim Biophys Acta. 1832:391–399. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bid HK, Zhan J, Phelps DA, Kurmasheva RT
and Houghton PJ: Potent inhibition of angiogenesis by the IGF-1
receptor-targeting antibody SCH717454 is reversed by IGF-2. Mol
Cancer Ther. 11:649–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Glass K, Fines C, Coulter P, Jena L,
McCarthy HO and Buckley N: Development and characterization of a
peptide-bisphosphonate nanoparticle for the treatment of breast
cancer. Mol Pharm. 21:4970–4982. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ishikawa T: Differences between zoledronic
acid and denosumab for breast cancer treatment. J Bone Miner Metab.
41:301–306. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tang X, Zhang Q, Shi S, Yen Y, Li X, Zhang
Y, Zhou K and Le AD: Bisphosphonates suppress insulin-like growth
factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling
pathways in human breast cancer cells. Int J Cancer. 126:90–103.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Seo SH, Hwang SY, Hwang S, Han S, Park H,
Lee YS, Rho SB and Kwon Y: Hypoxia-induced ELF3 promotes tumor
angiogenesis through IGF1/IGF1R. EMBO Rep. 23:e529772022.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu X, He H, Zhang F, Hu X, Bi F, Li K, Yu
H, Zhao Y, Teng X, Li J, et al: m6A methylated EphA2 and VEGFA
through IGF2BP2/3 regulation promotes vasculogenic mimicry in
colorectal cancer via PI3K/AKT and ERK1/2 signaling. Cell Death
Dis. 13:4832022. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Slater T, Haywood NJ, Matthews C, Cheema H
and Wheatcroft SB: Insulin-like growth factor binding proteins and
angiogenesis: From cancer to cardiovascular disease. Cytokine
Growth Factor Rev. 46:28–35. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Nijaguna MB, Patil V, Urbach S, Shwetha
SD, Sravani K, Hegde AS, Chandramouli BA, Arivazhagan A, Marin P,
Santosh V and Somasundaram K: Glioblastoma-derived macrophage
colony-stimulating factor (MCSF) induces microglial release of
insulin-like growth factor-binding protein 1 (IGFBP1) to promote
angiogenesis. J Biol Chem. 290:23401–23415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shen X, Xi G, Wai C and Clemmons DR: The
coordinate cellular response to insulin-like growth factor-I
(IGF-I) and insulin-like growth factor-binding protein-2 (IGFBP-2)
is regulated through vimentin binding to receptor tyrosine
phosphatase β (RPTPβ). J Biol Chem. 290:11578–11590. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ma YS, Shi BW, Guo JH, Liu JB, Yang XL,
Xin R, Shi Y, Zhang DD, Lu GX, Jia CY, et al: microRNA-320b
suppresses HNF4G and IGF2BP2 expression to inhibit angiogenesis and
tumor growth of lung cancer. Carcinogenesis. 42:762–771. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wei LF, Weng XF, Huang XC, Peng YH, Guo HP
and Xu YW: IGFBP2 in cancer: Pathological role and clinical
significance (Review). Oncol Rep. 45:427–438. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li X, He S and Ma B: Autophagy and
autophagy-related proteins in cancer. Mol Cancer. 19:122020.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Li X, Yang KB, Chen W, Mai J, Wu XQ, Sun
T, Wu RY, Jiao L, Li DD, Ji J, et al: CUL3 (cullin 3)-mediated
ubiquitination and degradation of BECN1 (beclin 1) inhibit
autophagy and promote tumor progression. Autophagy. 17:4323–4340.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Huangfu L, Wang X, Tian S, Chen J, Wang X,
Fan B, Yao Q, Wang G, Chen C, Han J, et al: Piceatannol enhances
Beclin-1 activity to suppress tumor progression and its combination
therapy strategy with everolimus in gastric cancer. Sci China Life
Sci. 66:298–312. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Filali-Mouncef Y, Hunter C, Roccio F,
Zagkou S, Dupont N, Primard C, Proikas-Cezanne T and Reggiori F:
The ménage à trois of autophagy, lipid droplets and liver disease.
Autophagy. 18:50–72. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wen ZP, Zeng WJ, Chen YH, Li H, Wang JY,
Cheng Q, Yu J, Zhou HH, Liu ZZ, Xiao J and Chen XP: Knockdown ATG4C
inhibits gliomas progression and promotes temozolomide
chemosensitivity by suppressing autophagic flux. J Exp Clin Cancer
Res. 38:2982019. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Masliah-Planchon J, Garinet S and Pasmant
E: RAS-MAPK pathway epigenetic activation in cancer: miRNAs in
action. Oncotarget. 7:38892–38907. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chen PC, Kuo YC, Chuong CM and Huang YH:
Niche modulation of IGF-1R signaling: its role in stem cell
pluripotency, cancer reprogramming and therapeutic applications.
Front Cell Dev Biol. 8:6259432021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lyons A, Coleman M, Riis S, Favre C,
O'Flanagan CH, Zhdanov AV, Papkovsky DB, Hursting SD and O'Connor
R: Insulin-like growth factor 1 signaling is essential for
mitochondrial biogenesis and mitophagy in cancer cells. J Biol
Chem. 292:16983–16998. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Riis S, Murray JB and O'Connor R: IGF-1
signalling regulates mitochondria dynamics and turnover through a
conserved GSK-3β-Nrf2-BNIP3 pathway. Cells. 9:1472020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Gao T, Liu X, He B, Pan Y and Wang S: IGF2
loss of imprinting enhances colorectal cancer stem cells
pluripotency by promoting tumor autophagy. Aging (Albany NY).
12:21236–21252. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Cai Q, Dozmorov M and Oh Y:
IGFBP-3/IGFBP-3 receptor system as an anti-tumor and
anti-metastatic signaling in cancer. Cells. 9:12612020. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Grkovic S, O'Reilly VC, Han S, Hong M,
Baxter RC and Firth SM: IGFBP-3 binds GRP78, stimulates autophagy
and promotes the survival of breast cancer cells exposed to adverse
microenvironments. Oncogene. 32:2412–2420. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chen X, Shao C, Liu J, Sun H, Yao B, Ma C,
Xu H and Zhu W: ULK2 suppresses ovarian cancer cell migration and
invasion by elevating IGFBP3. PeerJ. 12:e176282024. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lin JC, Liu TP, Chen YB and Yang PM:
PF-429242 exhibits anticancer activity in hepatocellular carcinoma
cells via FOXO1-dependent autophagic cell death and
IGFBP1-dependent anti-survival signaling. Am J Cancer Res.
13:4125–4144. 2023.PubMed/NCBI
|
|
60
|
Xia P, Zhang H, Lu H, Xu K, Jiang X, Jiang
Y, Gongye X, Chen Z, Liu J, Chen X, et al: METTL5 stabilizes c-Myc
by facilitating USP5 translation to reprogram glucose metabolism
and promote hepatocellular carcinoma progression. Cancer Commun
(Lond). 43:338–364. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Jing Z, Liu Q, He X, Jia Z, Xu Z, Yang B
and Liu P: NCAPD3 enhances Warburg effect through c-myc and E2F1
and promotes the occurrence and progression of colorectal cancer. J
Exp Clin Cancer Res. 41:1982022. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Okuyama T, Kyohara M, Terauchi Y and
Shirakawa J: The roles of the IGF axis in the regulation of the
metabolism: interaction and difference between insulin receptor
signaling and IGF-I receptor signaling. Int J Mol Sci. 22:68172021.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Ravera S, Puddu A, Bertola N, Verzola D,
Russo E, Maggi D and Panfoli I: IGF-1 signaling modulates oxidative
metabolism and stress resistance in ARPE-19 cells through PKM2
function. Int J Mol Sci. 25:136402024. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Stanley TL, Fourman LT, Zheng I, McClure
CM, Feldpausch MN, Torriani M, Corey KE, Chung RT, Lee H, Kleiner
DE, et al: Relationship of IGF-1 and IGF-binding proteins to
disease severity and glycemia in nonalcoholic fatty liver disease.
J Clin Endocrinol Metab. 106:e520–e533. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kasprzak A: Insulin-Like growth factor 1
(IGF-1) signaling in glucose metabolism in colorectal cancer. Int J
Mol Sci. 22:64342021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Lenz G, Hamilton A, Geng S, Hong T, Kalkum
M, Momand J, Kane SE and Huss JM: t-Darpp Activates IGF-1R
signaling to regulate glucose metabolism in trastuzumab-resistant
breast cancer cells. Clin Cancer Res. 24:1216–1226. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Lung Cancer Cohort Consortium (LC3), . The
blood proteome of imminent lung cancer diagnosis. Nat Commun.
14:30422023. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Cai G, Qi Y, Wei P, Gao H, Xu C, Zhao Y,
Qu X, Yao F and Yang W: IGFBP1 sustains cell survival during
spatially-confined migration and promotes tumor metastasis. Adv Sci
(Weinh). 10:e22065402023. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Onkar SS, Carleton NM, Lucas PC, Bruno TC,
Lee AV, Vignali DAA and Oesterreich S: The great immune escape:
Understanding the divergent immune response in breast cancer
subtypes. Cancer Discov. 13:23–40. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Leuzzi G, Vasciaveo A, Taglialatela A,
Chen X, Firestone TM, Hickman AR, Mao W, Thakar T, Vaitsiankova A,
Huang JW, et al: SMARCAL1 is a dual regulator of innate immune
signaling and PD-L1 expression that promotes tumor immune evasion.
Cell. 187:861–881.e32. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
De Martino M, Rathmell JC, Galluzzi L and
Vanpouille-Box C: Cancer cell metabolism and antitumour immunity.
Nat Rev Immunol. 24:654–669. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Huang Y, Huang L, Zhu J, Wu Y, Shi J and
Dai K: Differential expression of insulin-like growth factor type 1
receptor identifies heterogeneous intrahepatic regulatory T subsets
in mouse hepatocellular carcinoma. Clin Exp Immunol. 208:47–59.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Liu M, Zhong YB, Shao J, Zhang C and Shi
C: Tumor-associated macrophages promote human hepatoma Huh-7 cell
migration and invasion through the Gli2/IGF-II/ERK1/2 axis by
secreting TGF-β1. Cancer Biol Ther. 21:1041–1050. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Lv J, Liu C, Chen FK, Feng ZP, Jia L, Liu
PJ, Yang ZX, Hou F and Deng ZY: M2-like tumour-associated
macrophage-secreted IGF promotes thyroid cancer stemness and
metastasis by activating the PI3K/AKT/mTOR pathway. Mol Med Rep.
24:6042021. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Uehara H, Kobayashi T, Matsumoto M,
Watanabe S, Yoneda A and Bando Y: Adipose tissue:Critical
contributor to the development of prostate cancer. J Med Invest.
65:9–17. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Manzella L, Massimino M, Stella S, Tirrò
E, Pennisi MS, Martorana F, Motta G, Vitale SR, Puma A, Romano C,
et al: Activation of the IGF axis in thyroid cancer: Implications
for tumorigenesis and treatment. Int J Mol Sci. 20:32582019.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Xie X, Zhu Y, Cheng H, Li H, Zhang Y, Wang
R, Li W and Wu F: BPA exposure enhances the metastatic aggression
of ovarian cancer through the ERα/AKT/mTOR/HIF-1α signaling axis.
Food Chem Toxicol. 176:1137922023. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Zhang J, Chen B, Li H, Wang Y, Liu X, Wong
KY, Chan WN, Chan AK, Cheung AH, Leung KT, et al: Cancer-associated
fibroblasts potentiate colorectal cancer progression by crosstalk
of the IGF2-IGF1R and Hippo-YAP1 signaling pathways. J Pathol.
259:205–219. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Wei H, Dong C and Shen Z:
Kallikrein-related peptidase (KLK10) cessation blunts colorectal
cancer cell growth and glucose metabolism by regulating the
PI3K/Akt/mTOR pathway. Neoplasma. 67:889–897. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Lu X, Song X, Hao X, Liu X, Zhang X, Yuan
N, Ma H and Zhang Z: miR-186-3p attenuates the tumorigenesis of
cervical cancer via targeting insulin-like growth factor 1 to
suppress PI3K-Akt signaling pathway. Bioengineered. 12:7079–7092.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wang C, Sun Y, Cong S and Zhang F:
Insulin-like growth factor-1 promotes human uterine leiomyoma cell
proliferation via PI3K/AKT/mTOR pathway. Cells Tissues Organs.
212:194–202. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Gao C, He XF, Xu QR, Xu YJ and Shen J:
Sevoflurane downregulates insulin-like growth factor-1 to inhibit
cell proliferation, invasion and trigger apoptosis in glioma
through the PI3K/AKT signaling pathway. Anticancer Drugs.
30:e07442019. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Rieder S, Michalski CW, Friess H and
Kleeff J: Insulin-like growth factor signaling as a therapeutic
target in pancreatic cancer. Anticancer Agents Med Chem.
11:427–433. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Guo C, Cho KS, Li Y, Tchedre K, Antolik C,
Ma J, Chew J, Utheim TP, Huang XA, Yu H, et al: IGFBPL1 regulates
axon growth through IGF-1-mediated signaling cascades. Sci Rep.
8:20542018. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Liu Y, Zhang M, He T, Yang W, Wang L,
Zhang L and Guo M: Epigenetic silencing of IGFBPL1 promotes
esophageal cancer growth by activating PI3K-AKT signaling. Clin
Epigenetics. 12:222020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Guo Q, Jin Y, Chen X, Shen X, Lin M, Zeng
C, Zhou T and Zhang J: NF-κB in biology and targeted therapy: New
insights and translational implications. Signal Transduct Target
Ther. 9:532024. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Zhang L, Dou X, Zheng Z, Ye C, Lu TX,
Liang HL, Wang L, Weichselbaum RR and He C: YTHDF2/m6 A/NF-κB axis
controls anti-tumor immunity by regulating intratumoral Tregs. EMBO
J. 42:e1131262023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Harvey AE, Lashinger LM, Hays D, Harrison
LM, Lewis K, Fischer SM and Hursting SD: Calorie restriction
decreases murine and human pancreatic tumor cell growth, nuclear
factor-κB activation and inflammation-related gene expression in an
insulin-like growth factor-1-dependent manner. PLoS One.
9:e941512014. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Wang C, An Y, Wang Y, Shen K, Wang X, Luan
W, Ma F, Ni L, Liu M and Yu L: Insulin-like growth factor-I
activates NFκB and NLRP3 inflammatory signalling via ROS in cancer
cells. Mol Cell Probes. 52:1015832020. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Wang SH, Chen YL, Hsiao JR, Tsai FY, Jiang
SS, Lee AY, Tsai HJ and Chen YW: Insulin-like growth factor binding
protein 3 promotes radiosensitivity of oral squamous cell carcinoma
cells via positive feedback on NF-κB/IL-6/ROS signaling. J Exp Clin
Cancer Res. 40:952021. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Kim MS and Lee DY: Insulin-like growth
factor binding protein-3 enhances etoposide-induced cell growth
inhibition by suppressing the NF-κB activity in gastric cancer
cells. Mol Cell Biochem. 403:107–113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Cao Y, Chen J, Ren G, Zhang Y, Tan X and
Yang L: Punicalagin prevents inflammation in LPS-Induced RAW264.7
macrophages by inhibiting FoxO3a/autophagy signaling pathway.
Nutrients. 11:27942019. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Peluso I, Yarla NS, Ambra R, Pastore G and
Perry G: MAPK signalling pathway in cancers: Olive products as
cancer preventive and therapeutic agents. Semin Cancer Biol.
56:185–195. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Zhang Y, Moerkens M, Ramaiahgari S, de
Bont H, Price L, Meerman J and van de Water B: Elevated
insulin-like growth factor 1 receptor signaling induces
antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling
routes. Breast Cancer Res. 13:R522011. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Rao W, Li H, Song F, Zhang R, Yin Q, Wang
Y, Xi Y and Ge H: OVA66 increases cell growth, invasion and
survival via regulation of IGF-1R-MAPK signaling in human cancer
cells. Carcinogenesis. 35:1573–1581. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Teng JA, Wu SG, Chen JX, Li Q, Peng F, Zhu
Z, Qin J and He ZY: The activation of ERK1/2 and JNK MAPK signaling
by insulin/IGF-1 Is responsible for the development of colon cancer
with type 2 diabetes Mellitus. PLoS One. 11:e01498222016.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang
X, Zhou Z, Shu G and Yin G: Wnt/β-catenin signalling: Function,
biological mechanisms and therapeutic opportunities. Signal
Transduct Target Ther. 7:32022. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Yu F, Yu C, Li F, Zuo Y, Wang Y, Yao L, Wu
C, Wang C and Ye L: Wnt/β-catenin signaling in cancers and targeted
therapies. Signal Transduct Target Ther. 6:3072021. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Xue W, Yang L, Chen C, Ashrafizadeh M,
Tian Y and Sun R: Wnt/β-catenin-driven EMT regulation in human
cancers. Cell Mol Life Sci. 81:792024. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Chatterjee A, Paul S, Bisht B,
Bhattacharya S, Sivasubramaniam S and Paul MK: Advances in
targeting the WNT/β-catenin signaling pathway in cancer. Drug
Discov Today. 27:82–101. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Hsieh CH, Cheng LH, Hsu HH, Ho TJ, Tu CC,
Lin YM, Chen MC, Tsai FJ, Hsieh YL and Huang CY: Apicidin-resistant
HA22T hepatocellular carcinoma cells strongly activated the
Wnt/β-catenin signaling pathway and MMP-2 expression via the
IGF-IR/PI3K/Akt signaling pathway enhancing cell metastatic effect.
Biosci Biotechnol Biochem. 77:2397–2404. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Jamwal G, Singh G, Dar MS, Singh P, Bano
N, Syed SH, Sandhu P, Akhter Y, Monga SP and Dar MJ: Identification
of a unique loss-of-function mutation in IGF1R and a crosstalk
between IGF1R and Wnt/β-catenin signaling pathways. Biochim Biophys
Acta Mol Cell Res. 1865:920–931. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Zhang QY, Wang L, Song ZY and Qu XJ:
Knockdown of type I insulin-like growth factor receptor inhibits
human colorectal cancer cell growth and downstream PI3K/Akt,
WNT/β-catenin signal pathways. Biomed Pharmacother. 73:12–18. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Chen KC, Chen PH, Ho KH, Shih CM, Chou CM,
Cheng CH and Lee CC: IGF-1-enhanced miR-513a-5p signaling
desensitizes glioma cells to temozolomide by targeting the
NEDD4L-inhibited Wnt/β-catenin pathway. PLoS One. 14:e02259132019.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Hashemi Goradel N, Najafi M, Salehi E,
Farhood B and Mortezaee K: Cyclooxygenase-2 in cancer: A review. J
Cell Physiol. 234:5683–5699. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Peng Y, Wang Y, Tang N, Sun D, Lan Y, Yu
Z, Zhao X, Feng L, Zhang B, Jin L, et al: Andrographolide inhibits
breast cancer through suppressing COX-2 expression and angiogenesis
via inactivation of p300 signaling and VEGF pathwa. J Exp Clin
Cancer Res. 37:2482018. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Huang R, Yu J, Zhang B, Li X, Liu H and
Wang Y: Emerging COX-2 inhibitors-based nanotherapeutics for cancer
diagnosis and treatment. Biomaterials. 315:1229542025. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Song KH, Kang JH, Woo JK, Nam JS, Min HY,
Lee HY, Kim SY and Oh SH: The novel IGF-IR/Akt-dependent anticancer
activities of glucosamine. BMC Cancer. 14:312014. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Stoeltzing O, Liu W, Fan F, Wagner C,
Stengel K, Somcio RJ, Reinmuth N, Parikh AA, Hicklin DJ and Ellis
LM: Regulation of cyclooxygenase-2 (COX-2) expression in human
pancreatic carcinoma cells by the insulin-like growth factor-I
receptor (IGF-IR) system. Cancer Lett. 258:291–300. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Tian J, Lambertz I, Berton TR, Rundhaug
JE, Kiguchi K, Shirley SH, Digiovanni J, Conti CJ, Fischer SM and
Fuchs-Young R: Transgenic insulin-like growth factor-1 stimulates
activation of COX-2 signaling in mammary glands. Mol Carcinog.
51:973–983. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Li W, Sun D, Lv Z, Wei Y, Zheng L, Zeng T
and Zhao J: Insulin-like growth factor binding protein-4 inhibits
cell growth, migration and invasion and downregulates COX-2
expression in A549 lung cancer cells. Cell Biol Int. 41:384–391.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Mengzhe G, Shanshan X, Di Z and Shihua W:
Editorial: The role of the IGF axis in tumorigenesis and cancer
treatment: From genes to metabolites. Front Endocrinol (Lausanne).
13:11239622023. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Wang P, Mak VC and Cheung LW: Drugging
IGF-1R in cancer: New insights and emerging opportunities. Genes
Dis. 10:199–211. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Fuentes-Baile M, Ventero MP, Encinar JA,
García-Morales P, Poveda-Deltell M, Pérez-Valenciano E, Barberá VM,
Gallego-Plazas J, Rodríguez-Lescure Á, Martín-Nieto J and Saceda M:
Differential effects of IGF-1R small molecule tyrosine kinase
inhibitors BMS-754807 and OSI-906 on human cancer cell lines.
Cancers (Basel). 12:37172020. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Stan MN and Krieger CC: The adverse
effects profile of teprotumumab. J Clin Endocrinol Metab.
108:e654–e662. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Zhang J, Wen G, Sun L, Yuan W, Wang R,
Zeng Q, Zhang G and Yu B: Cryptotanshinone inhibits cellular
proliferation of human lung cancer cells through downregulation of
IGF-1R/PI3K/Akt signaling pathway. Oncol Rep. 40:2926–2934.
2018.PubMed/NCBI
|
|
117
|
Jung M, Bu SY, Tak KH, Park JE and Kim E:
Anticarcinogenic effect of quercetin by inhibition of insulin-like
growth factor (IGF)-1 signaling in mouse skin cancer. Nutr Res
Pract. 7:439–445. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Le CT, Leenders WPJ, Molenaar RJ and van
Noorden CJF: Effects of the green tea polyphenol
epigallocatechin-3-gallate on glioma: A critical evaluation of the
literature. Nutr Cancer. 70:317–333. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Liu F, Ye S, Zhao L and Niu Q: The role of
IGF/IGF-1R signaling in the regulation of cancer stem cells. Clin
Transl Oncol. 26:2924–2934. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Ding F and Yang S:
Epigallocatechin-3-gallate inhibits proliferation and triggers
apoptosis in colon cancer via the hedgehog/phosphoinositide
3-kinase pathways. Can J Physiol Pharmacol. 99:910–920. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Gao J, Chesebrough JW, Cartlidge SA,
Ricketts SA, Incognito L, Veldman-Jones M, Blakey DC, Tabrizi M,
Jallal B, Trail PA, et al: Dual IGF-I/II-neutralizing antibody
MEDI-573 potently inhibits IGF signaling and tumor growth. Cancer
Res. 71:1029–1040. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Kim JH, Choi DS, Lee OH, Oh SH, Lippman SM
and Lee HY: Antiangiogenic antitumor activities of IGFBP-3 are
mediated by IGF-independent suppression of Erk1/2 activation and
Egr-1-mediated transcriptional events. Blood. 118:2622–2631. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Gao S, Sun Y, Zhang X, Hu L, Liu Y, Chua
CY, Phillips LM, Ren H, Fleming JB, Wang H, et al: IGFBP2 Activates
the NF-κB pathway to drive epithelial-mesenchymal transition and
invasive character in pancreatic ductal adenocarcinoma. Cancer Res.
76:6543–6554. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Cai Q, Kim M, Harada A, Idowu MO,
Sundaresan G, Zweit J and Oh Y: Alpha-1 Antitrypsin inhibits
tumorigenesis and progression of colitis-associated colon cancer
through suppression of inflammatory neutrophil-activated serine
proteases and IGFBP-3 proteolysis. Int J Mol Sci. 23:137372022.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Wei X, Huo Y, Pi J, Gao Y, Rao S, He M,
Wei Q, Song P, Chen Y, Lu D, et al: METTL3 preferentially enhances
non-m6A translation of epigenetic factors and promotes
tumourigenesis. Nat Cell Biol. 24:1278–1290. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
He P, Liu X, Yu G, Wang Y, Wang S, Liu J
and An Y: METTL3 facilitates prostate cancer progression via
inducing HOXC6 m6A modification and stabilizing its expression
through IGF2BP2-dependent mechanisms. Mol Cell Biochem.
479:1707–1720. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Chen X, Wang M, Wang H, Yang J, Li X,
Zhang R, Ding X, Hou H, Zhou J and Wu M: METTL3 inhibitor
suppresses the progression of prostate cancer via IGFBP3/AKT
pathway and synergizes with PARP inhibitor. Biomed Pharmacother.
179:1173662024. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Pomeroy AE, Schmidt EV, Sorger PK and
Palmer AC: Drug independence and the curability of cancer by
combination chemotherapy. Trends Cancer. 8:915–929. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Dias MP, Moser SC, Ganesan S and Jonkers
J: Understanding and overcoming resistance to PARP inhibitors in
cancer therapy. Nat Rev Clin Oncol. 18:773–791. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Ravi P, Wang V, Fichorova RN, McGregor B,
Wei XX, Basaria S and Sweeney CJ: IGF-1 axis changes with ADT and
docetaxel in metastatic prostate cancer. Endocr Relat Cancer.
30:e2302412023. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Codony-Servat J, Cuatrecasas M, Asensio E,
Montironi C, Martínez-Cardús A, Marín-Aguilera M, Horndler C,
Martínez-Balibrea E, Rubini M, Jares P, et al: Nuclear IGF-1R
predicts chemotherapy and targeted therapy resistance in metastatic
colorectal cancer. Br J Cancer. 117:1777–1786. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Qiu N, He YF, Zhang SM, Zhan YT, Han GD,
Jiang M, He WX, Zhou J, Liang HL, Ao X, et al: Cullin7 enhances
resistance to trastuzumab therapy in Her2 positive breast cancer
via degrading IRS-1 and downregulating IGFBP-3 to activate the
PI3K/AKT pathway. Cancer Lett. 464:25–36. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Xu Z, Wang X, Sun W, Xu F, Kou H, Hu W,
Zhang Y, Jiang Q, Tang J and Xu Y: RelB-activated GPX4 inhibits
ferroptosis and confers tamoxifen resistance in breast cancer.
Redox Biol. 68:1029522023. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Zheng Y, Sowers JY and Houston KD: IGFBP-1
expression promotes tamoxifen resistance in breast cancer cells via
Erk pathway activation. Front Endocrinol (Lausanne). 11:2332020.
View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Suzuki H, Iwamoto H, Seki T, Nakamura T,
Masuda A, Sakaue T, Tanaka T, Imamura Y, Niizeki T, Nakano M, et
al: Tumor-derived insulin-like growth factor-binding protein-1
contributes to resistance of hepatocellular carcinoma to tyrosine
kinase inhibitors. Cancer Commun (Lond). 43:415–434. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Lu H, Ai J, Zheng Y, Zhou W, Zhang L, Zhu
J, Zhang H and Wang S: IGFBP2/ITGA5 promotes gefitinib resistance
via activating STAT3/CXCL1 axis in non-small cell lung cancer. Cell
Death Dis. 15:4472024. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Coleman KL, Chiaramonti M, Haddad B,
Ranzenberger R, Henning H, Al Khashali H, Ray R, Darweesh B,
Guthrie J, Heyl D and Evans HG: Phosphorylation of IGFBP-3 by
casein kinase 2 blocks its interaction with hyaluronan, enabling
HA-CD44 signaling leading to increased NSCLC cell survival and
cisplatin resistance. Cells. 12:4052023. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Chen X, Lu Q, Zhou H, Liu J, Nadorp B,
Lasry A, Sun Z, Lai B, Rona G, Zhang J, et al: A
membrane-associated MHC-I inhibitory axis for cancer immune
evasion. Cell. 186:3903–3920.e21. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Yu L, Ding Y, Wan T, Deng T, Huang H and
Liu J: Significance of CD47 and Its association with tumor immune
microenvironment heterogeneity in ovarian cancer. Front Immunol.
12:7681152021. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Sun Y, Yin Z, Li S, Wu L, Zhang Y, Zhao Y,
Gomes Dos Santos IL, Subudhi S, Lei P, Muzikansky A, et al:
Losartan rewires the tumor-immune microenvironment and suppresses
IGF-1 to overcome resistance to chemo-immunotherapy in ovarian
cancer. Br J Cancer. 131:1683–1693. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Song D, Wu Y, Li J, Liu J, Yi Z, Wang X,
Sun J, Li L, Wu Q, Chen Y, et al: Insulin-like growth factor 2
drives fibroblast-mediated tumor immunoevasion and confers
resistance to immunotherapy. J Clin Invest. 134:e1833662024.
View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Hashimoto M, Konda JD, Perrino S, Celia
Fernandez M, Lowy AM and Brodt P: Targeting the IGF-Axis
potentiates immunotherapy for pancreatic ductal adenocarcinoma
liver metastases by altering the immunosuppressive
microenvironment. Mol Cancer Ther. 20:2469–2482. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Pointer KB, Pitroda SP and Weichselbaum
RR: Radiotherapy and immunotherapy: Open questions and future
strategies. Trends Cancer. 8:9–20. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Hessels AC, Langendijk JA, Gawryszuk A,
Heersters MAAM, van der Salm NLM, Tissing WJE, van der Weide HL and
Maduro JH: Review-Late toxicity of abdominal and pelvic
radiotherapy for childhood cancer. Radiother Oncol. 170:27–36.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Zong R, Chen X, Feng J and Xu S: IGF-1R
depletion sensitizes colon cancer cell lines to radiotherapy.
Cancer Biomark. 32:199–206. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Chen L, Zhu Z, Gao W, Jiang Q, Yu J and Fu
C: Systemic analysis of different colorectal cancer cell lines and
TCGA datasets identified IGF-1R/EGFR-PPAR-CASPASE axis as important
indicator for radiotherapy sensitivity. Gene. 627:484–490. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Chen JH, T H Wu A, T W Tzeng D, Huang CC,
Tzeng YM and Chao TY: Antrocin, a bioactive component from Antrodia
cinnamomea, suppresses breast carcinogenesis and stemness via
downregulation of β-catenin/Notch1/Akt signaling. Phytomedicine.
52:70–78. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Su YH, Wu JS, Dai YZ, Chen YT, Lin YX,
Tzeng YM and Liao JW: Anti-oxidant, anti-mutagenic activity and
safety evaluation of antrocin. Toxics. 11:5472023. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Chen YA, Tzeng DTW, Huang YP, Lin CJ, Lo
UG, Wu CL, Lin H, Hsieh JT, Tang CH and Lai CH: Antrocin sensitizes
prostate cancer cells to radiotherapy through inhibiting PI3K/AKT
and MAPK signaling pathways. Cancers (Basel). 11:342018. View Article : Google Scholar : PubMed/NCBI
|
